Titre du document / Document title

Mifepristone and misoprostol and methotrexate/misoprostol in clinical practice for abortion

Auteur(s) / Author(s)

CREININ Mitchell D. ; POTTER Cynthia ; HOLOVANISIN Maria ; JANCZUKIEWICZ Lynn ; PYMAR Helen C. ; SCHWARTZ Jill L. ; MEYN Leslie ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

Department of Obstetrics, Gynecology, and Women's Health, University of Pittsburgh Physicians, ETATS-UNIS
Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh, ETATS-UNIS

Résumé / Abstract

OBJECTIVE: The purpose of this study was to evaluate the efficacy, side-effect profile, and follow-up rates in women who obtain a medical abortion in a nonresearch setting. STUDY DESIGN: From December 1, 2000, to June 30, 2001, we prospectively followed 218 women who had been evaluated in our private office for medical abortion. Women received either mifepristone 200 mg orally followed 1 to 2 days later by self-administered misoprostol 800 μg vaginally or methotrexate 50 mg/m² intramuscularly followed 3 to 7 days later by self-administered misoprostol 800 μg vaginally. RESULTS: Of the 174 women who had a medical abortion, 148 women (85%) chose mifepristone/misoprostol, and 26 women (15%) chose methotrexate/misoprostol. In women up to 49 days of gestation, complete abortion occurred by the first follow-up visit in 82 of 86 women (95%; 95% Cl, 89-99) and in 21 of 25 women (84%; 95% Cl, 64-95) women, respectively. In women who used mifepristone/misoprostol from 50 to 63 days of gestation, complete abortions occurred in 56 of 59 women (95%; 95% Cl, 86-99) women. Four women (2%; 95% Cl, 1-6) were lost to follow-up. CONCLUSION: Medical abortion with mifepristone/misoprostol and with methotrexate/misoprostol can be provided in a nonresearch setting with efficacy similar to that reported in the medical literature for research protocols.

Revue / Journal Title

American journal of obstetrics and gynecology   ISSN 0002-9378   CODEN AJOGAH 

Source / Source

2003, vol. 188, n^o3, pp. 664-669 [6 page(s) (article)] (25 ref.)

Langue / Language

Anglais

Editeur / Publisher

Elsevier, Philadelphia, PA, ETATS-UNIS  (1920) (Revue)

Mots-clés anglais / English Keywords

Antifolate ; Antimetabolic ; Abortifacient ; Antihormone ; Prostaglandin derivatives ; Toxicity ; Secondary effect ; Comparative study ; Follow up study ; Treatment efficiency ; Drug combination ; Methotrexate ; Female ; Human ; Misoprostol ; Therapeutic abortion ; Association ; Mifepristone ;

Mots-clés français / French Keywords

Antifolate ; Antimétabolite ; Abortif ; Antihormone ; Prostaglandine dérivé ; Toxicité ; Effet secondaire ; Etude comparative ; Etude longitudinale ; Efficacité traitement ; Association médicamenteuse ; Méthotrexate ; Femelle ; Homme ; Misoprostol ; Avortement thérapeutique ; Association ; Mifépristone ;

Mots-clés espagnols / Spanish Keywords

Antifolato ; Antimetabólito ; Abortivo ; Antihormona ; Prostaglandina derivado ; Toxicidad ; Efecto secundario ; Estudio comparativo ; Estudio longitudinal ; Eficacia tratamiento ; Asociación medicamentosa ; Metotrexato ; Hembra ; Hombre ; Misoprostol ; Aberto terapéutico ; Asociación ; Mifepristona ;

Mots-clés d'auteur / Author Keywords

Medical abortion ; mifepristone ; methotrexate ; misoprostol ;

Localisation / Location

INIST-CNRS, Cote INIST : 3053, 35400010951698.0110